W. Xia, Lei-hua Liu, P. Ho, N. Spector (2004)
Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016Oncogene, 23
Yuhong Lu, X. Zi, Yunhua Zhao, D. Mascarenhas, M. Pollak (2001)
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).Journal of the National Cancer Institute, 93 24
J. Shou, S. Massarweh, C. Osborne, A. Wakeling, Simale Ali, H. Weiss, R. Schiff (2004)
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.Journal of the National Cancer Institute, 96 12
G. Arpino, S. Green, D. Allred, D. Lew, S. Martino, C. Osborne, R. Elledge (2004)
HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast CancerClinical Cancer Research, 10
R. Nahta, L. Yuan, Bing Zhang, R. Kobayashi, F. Esteva (2005)
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.Cancer research, 65 23
D. Rajagopalan, Pankaj Agarwal (2005)
Inferring pathways from gene lists using a literature-derived network of biological relationshipsBioinformatics, 21 6
Binhua Zhou, Y. Liao, W. Xia, Y. Zou, B. Spohn, M. Hung (2001)
HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylationNature Cell Biology, 3
D. Mangelsdorf, C. Thummel, M. Beato, P. Herrlich, G. Schütz, K. Umesono, B. Blumberg, P. Kastner, M. Mark, P. Chambon, R. Evans (1995)
The nuclear receptor superfamily: The second decadeCell, 83
BL Smith, D. Chin, W. Maltzman, K. Crosby, G. Hortobagyi, SS Bacus (2004)
The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteinsBritish Journal of Cancer, 91
K. Mccarty, T. Barton, B. Fetter, B. Woodard, Jeffrey Mossler, W. Reeves, J. Daly, W. Wilkinson, K. Mccarty (1980)
Correlation of estrogen and progesterone receptors with histologic differentiation in mammary carcinomaCancer, 46
Fengzhi Li, E. Ackermann, C. Bennett, A. Rothermel, J. Plescia, S. Tognin, A. Villa, P. Marchisio, D. Altieri (1999)
Pleiotropic cell-division defects and apoptosis induced by interference with survivin functionNature Cell Biology, 1
D. Slamon, G. Clark, S. Wong, W. Levin, A. Ullrich, W. McGuire (1987)
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science, 235 4785
W. Xia, Catherine Gerard, Lei-hua Liu, N. Baudson, T. Ory, N. Spector (2005)
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cellsOncogene, 24
Yoichi Nagata, K. Lan, Xiaoyan Zhou, M. Tan, F. Esteva, A. Sahin, K. Klos, Ping Li, B. Monia, Nina Nguyen, G. Hortobagyi, M. Hung, Dihua Yu (2004)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.Cancer cell, 6 2
N. Spector, W. Xia, H. Burris, H. Hurwitz, E. Dees, A. Dowlati, B. O'Neil, B. Overmoyer, P. Marcom, K. Blackwell, Deborah Smith, K. Koch, A. Stead, S. Mangum, M. Ellis, Lei-hua Liu, A. Man, T. Bremer, Jennifer Harris, S. Bacus (2005)
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 11
E. Cutsem, P. Hoff, P. Harper, R. Bukowski, D. Cunningham, P. Dufour, U. Graeven, J. Lokich, S. Madajewicz, J. Maroun, J. Marshall, E. Mitchell, G. Pérez-Manga, P. Rougier, W. Schmiegel, J. Schoelmerich, A. Sobrero, R. Schilsky (2004)
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trialsBritish Journal of Cancer, 90
Xiaorui Yu, R. Rajala, J. McGinnis, Feng Li, R. Anderson, X. Yan, Sheng Li, R. Elias, R. Knapp, Xiaohong Zhou, W. Cao (2004)
Involvement of Insulin/Phosphoinositide 3-Kinase/Akt Signal Pathway in 17β-Estradiol-mediated Neuroprotection*Journal of Biological Chemistry, 279
G. Konecny, M. Pegram, N. Venkatesan, R. Finn, Guorong Yang, M. Rahmeh, M. Untch, D. Rusnak, G. Spehar, R. Mullin, B. Keith, T. Gilmer, M. Berger, K. Podratz, D. Slamon (2006)
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.Cancer research, 66 3
W. Xia, R. Mullin, B. Keith, Lei-hua Liu, Hong Ma, D. Rusnak, G. Owens, K. Alligood, N. Spector (2002)
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathwaysOncogene, 21
Dihua Yu, M. Hung (2000)
Overexpression of ErbB2 in cancer and ErbB2-targeting strategiesOncogene, 19
E. Smart, G. Graf, M. McNiven, W. Sessa, J. Engelman, P. Scherer, Takashi Okamoto, M. Lisanti (1999)
Caveolins, Liquid-Ordered Domains, and Signal TransductionMolecular and Cellular Biology, 19
G. Ambrosini, C. Adida, D. Altieri (1997)
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphomaNature Medicine, 3
H. Burris, H. Hurwitz, E. Dees, A. Dowlati, K. Blackwell, B. O'Neil, P. Marcom, M. Ellis, B. Overmoyer, Suzanne Jones, Jennifer Harris, Deborah Smith, K. Koch, A. Stead, S. Mangum, N. Spector (2005)
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 23
C. Cahill, G. Tzivion, N. Nasrin, S. Ogg, Justin Dore, G. Ruvkun, M. Alexander-Bridges (2001)
Phosphatidylinositol 3-Kinase Signaling Inhibits DAF-16 DNA Binding and Function via 14-3-3-dependent and 14-3-3-independent Pathways*The Journal of Biological Chemistry, 276
S. Bacus, D. Altomare, L. Lyass, D. Chin, M. Farrell, K. Gurova, A. Gudkov, J. Testa (2002)
AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survivalOncogene, 21
J. A.Pieter, Van Den, Heuvel, A. Schulze, B. Burgering (2005)
Direct control of caveolin-1 expression by FOXO transcription factors.The Biochemical journal, 385 Pt 3
Shangqin Guo, G. Sonenshein (2004)
Forkhead Box Transcription Factor FOXO3a Regulates Estrogen Receptor Alpha Expression and Is Repressed by the Her-2/neu/Phosphatidylinositol 3-Kinase/Akt Signaling PathwayMolecular and Cellular Biology, 24
J. Keen, E. Garrett-Mayer, Catherine Pettit, K. Mack, J. Manning, J. Herman, N. Davidson (2004)
Epigenetic regulation of protein phosphatase 2A (PP2A), Lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cellsCancer Biology & Therapy, 3
M. Cobleigh, C. Vogel, D. Tripathy, N. Robert, S. Scholl, L. Fehrenbacher, J. Wolter, V. Paton, S. Shak, G. Lieberman, D. Slamon (1999)
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 9
W. Xia, J. Bisi, J. Strum, Lei-hua Liu, K. Carrick, K. Graham, Amanda Treece, M. Hardwicke, Michael Dush, Q. Liao, R. Westlund, Sumin Zhao, S. Bacus, N. Spector (2006)
Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.Cancer research, 66 3
E. Tsai, Shao-Chun Wang, Jau-nan Lee, Mien Hung (2001)
Akt activation by estrogen in estrogen receptor-negative breast cancer cells.Cancer research, 61 23
Leila Vollenweider‐Zerargui, Laurent Barrelet, Y.N.S. Wong, T. Lemarchand-Béraud, F. Gomez (1986)
The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women °clinical correlation on 547 patientsCancer, 57
A. Schlegel, C. Wang, R. Pestell, M. Lisanti (2001)
Ligand-independent activation of oestrogen receptor alpha by caveolin-1.The Biochemical journal, 359 Pt 1
Binhua Zhou, Y. Liao, W. Xia, B. Spohn, Mong-Hong Lee, M. Hung (2001)
Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cellsNature Cell Biology, 3
G. Hortobagyi, M. Hung, A. Buzdar (1999)
Recent developments in breast cancer therapy.Seminars in oncology, 26 4 Suppl 12
Carolyn Smith, Z. Nawaz, B. O’Malley (1997)
Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen.Molecular endocrinology, 11 6
E. Peles, R. Ben-Levy, E. Tzahar, Naili Liu, '. DuanzhiWen, Y. Yarden (1993)
Cell‐type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER‐2 suggests complex ligand‐receptor relationships.The EMBO Journal, 12
C. Osborne, V. Bardou, T. Hopp, G. Chamness, S. Hilsenbeck, S. Fuqua, J. Wong, D. Allred, G. Clark, R. Schiff (2003)
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.Journal of the National Cancer Institute, 95 5
S. Cockerill, C. Stubberfield, J. Stables, M. Carter, S. Guntrip, K. Smith, S. McKeown, R. Shaw, P. Topley, L. Thomsen, K. Affleck, A. Jowett, D. Hayes, M. Willson, P. Woollard, D. Spalding (2001)
Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.Bioorganic & medicinal chemistry letters, 11 11
Binhua Zhou, M. Hu, S. Miller, Zhenming Yu, W. Xia, Shiaw-Yih Lin, M. Hung (2000)
HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway*The Journal of Biological Chemistry, 275
Proceedings of the National Academy of Sciences – Unpaywall
Published: May 9, 2006
Access the full text.
Sign up today, get DeepDyve free for 14 days.